Misconceptions Surrounding Hepatocellular Carcinoma
Nayantara Orekondy, Sheila Eswaran – 2 January 2019
Steroids for Severe Alcoholic Hepatitis: More Risk Than Reward?
Alexander Dao, Amol S. Rangnekar – 2 January 2019
Endoscopic Sedation of the Patient With Cirrhosis
Jerome C. Edelson, Don C. Rockey – 2 January 2019
PRO: Needle Exchange Programs Should Be Instituted to Reduce Hepatitis C Virus Transmission
Thomas G. Cotter, Matthew W. Stier, Andrew Aronsohn – 2 January 2019
Return to Alcohol Use After Liver Transplant: Patterns and Surveillance
Brian P. Lee, Norah A. Terrault – 2 January 2019
CON: Needle Exchange Programs Should Not Be Instituted to Reduce Hepatitis C Virus Transmission
Ken O’Riordan, Mohsen Khan, Andrew Mazulis – 2 January 2019
Increasing Awareness on Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma in the United States
Catherine T. Frenette – 1 January 2019
Issue Information
1 January 2019
Actin Depolymerization in Dedifferentiated Liver Sinusoidal Endothelial Cells Promotes Fenestrae Re‐Formation
Julie Di Martino, Patrice Mascalchi, Philippe Legros, Sabrina Lacomme, Etienne Gontier, Paulette Bioulac‐Sage, Charles Balabaud, Violaine Moreau, Frédéric Saltel – 28 December 2018 – Liver sinusoidal endothelial cells (LSECs) possess fenestrae, which are key for the exchange between blood and hepatocytes. Alterations in their number or diameter have important implications for hepatic function in liver diseases. They are lost early in the development of hepatic fibrosis through a process called capillarization.
Development of Hepatic Steatosis After Chemotherapy for Non‐Hodgkin Lymphoma
Gil Ben‐Yakov, Hawwa Alao, John P. Haydek, Nancy Fryzek, Min Ho Cho, Mehdi Hemmati, Vikram Samala, Margaret Shovlin, Kieron Dunleavy, Wyndham Wilson, Elizabeth C. Jones, Yaron Rotman – 28 December 2018 – Nonalcoholic fatty liver disease is the most common liver disorder in the developed world. Although typically reflecting caloric overload, it can also be secondary to drug toxicity. We aimed to describe the incidence and risk factors for de novo steatosis during chemotherapy for non‐Hodgkin lymphoma (NHL).